1048 related articles for article (PubMed ID: 25997572)
1. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
[TBL] [Abstract][Full Text] [Related]
3. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials.
Fabrizi F; Dixit V; Martin P; Messa P
J Viral Hepat; 2011 Jul; 18(7):e263-9. PubMed ID: 21108701
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
5. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT
Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584
[TBL] [Abstract][Full Text] [Related]
6. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
7. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
[TBL] [Abstract][Full Text] [Related]
8. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.
El Makhzangy H; Esmat G; Said M; Elraziky M; Shouman S; Refai R; Rekacewicz C; Gad RR; Vignier N; Abdel-Hamid M; Zalata K; Bedossa P; Pol S; Fontanet A; Mohamed MK
J Med Virol; 2009 Sep; 81(9):1576-83. PubMed ID: 19626613
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
[TBL] [Abstract][Full Text] [Related]
10. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
11. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
12. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.
Bruchfeld A; Lindahl K; Reichard O; Carlsson T; Schvarcz R
J Viral Hepat; 2006 May; 13(5):316-21. PubMed ID: 16637862
[TBL] [Abstract][Full Text] [Related]
14. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
15. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
16. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
17. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
[TBL] [Abstract][Full Text] [Related]
20. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
